To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Scientific result | Health ＆ life sciences | CBRN-E threats
Researchers from SIMoS, SCBM and Institut Curie, in collaboration with Carnegie Mellon University (USA), have identified the intracellular target and the mechanism of action of Retro-2, a broad-spectrum inhibitor of intracellular toxins and pathogens. They are now working on the design of an effective drug in the event of a bioterrorist attack or a health crisis.
The retrograde transport inhibitor Retro-2 has a protective effect on cells and in mice against Shiga-like toxins and ricin. Retro-2 causes toxin accumulation in early endosomes and relocalization of the Golgi SNARE protein syntaxin-5 to the endoplasmic reticulum. The molecular mechanisms by which this is achieved remain unknown. Here, we show that Retro-2 targets the endoplasmic reticulum exit site component Sec16A, affecting anterograde transport of syntaxin-5 from the endoplasmic reticulum to the Golgi. The formation of canonical SNARE complexes involving syntaxin-5 is not affected in Retro-2-treated cells. By contrast, the interaction of syntaxin-5 with a newly discovered binding partner, the retrograde trafficking chaperone GPP130, is abolished, and we show that GPP130 must indeed bind to syntaxin-5 to drive Shiga toxin transport from the endosomes to the Golgi. We therefore identify Sec16A as a druggable target and provide evidence for a non-SNARE function for syntaxin-5 in interaction with GPP130.See the CEA press release of February, 21, 2020
A Forrester, SJ Rathjen, MD Garcia-Castillo, C Bachert, A Couhert, L Tepshi, S Pichard, J Martinez, M Munier, R Sierocki, HF Renard, CA Valades-Cruz, F Dingli, D Loew, C Lamaze, JC Cintrat, AD Linstedt, D Gillet, J Barbier, L Johannes (2020) Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2. Nat.Chem.Biol, in press
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.